EDINBURGH, Scotland, Jan. 4, 2024
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the
"Company") (NASDAQ: TCBP) a clinical stage biotechnology
company developing platform allogeneic gamma-delta T cell therapies
for cancer, today announced that on January
2, 2024, the Company received a written notice from
The Nasdaq Stock Market ("Nasdaq"). The notice informed TC
BioPharm that it has regained compliance with the minimum bid price
requirement under NASDAQ Listing Rule 5550(a)(2) (the "Rule") for
continued listing on the Nasdaq Capital Market.
On June 22, 2023, TC BioPharm
was notified by Nasdaq that it was not in compliance with the
minimum bid price rule because its common stock failed to meet the
closing bid price of $1.00 or more
for 30 consecutive business days. To regain compliance with the
Rule, the Company's common shares were required to maintain a
minimum closing bid price of $1.00 or
more for at least 10 consecutive business days. This requirement
was met on December 29, 2023.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in
treatment of acute myeloid leukemia using the Company's proprietary
allogeneic CryoTC technology to provide frozen product to clinics
worldwide. TC BioPharm also maintains a robust pipeline for future
indications in solid tumors as well as a significant IP/patent
portfolio in the use of CARs with gamma-delta T cells and owns our
manufacturing facility to maintain cost and product quality
controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302026039.html
SOURCE TC BioPharm